Company intelligence / Profile preview

MindImmune Therapeutics, Inc.

Kingston, Rhode Island, United Statesmindimmune.com ↗

Ownership: Private
Development stage: Preclinical

Overview

MindImmune Therapeutics has discovered that peripheral innate immune cells infiltrate the brain and cause synaptic damage central to Alzheimer’s symptoms. Their lead preclinical program uses a novel antibody therapeutic to block this infiltration, aiming to arrest cognitive decline. The company has demonstrated rapid arrest of synaptic damage in preclinical models and aims to advance its lead candidate toward clinical trials. Additional programs target Huntington's disease and chronic neuropathic pain through similar immunomodulatory mechanisms.

Therapeutic areas: PsychiatryNeurology
Modalities: Monoclonal antibodies (therapeutic antibody)
Industry: Biotech

Drug pipeline

1 asset

MITI-101

Preclinical

Partnerships

Pfizer Ventures (investment & research collaboration on specialized immune cells)H. Lundbeck A/S (divestment of two preclinical programs; equity interest & milestones/royalties agreement)University of Rhode Island George & Anne Ryan Institute for Neuroscience (academic affiliation/collaboration)

Beyond the preview

Go deeper on MindImmune Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindImmune Therapeutics, Inc..

Explore the full profile